predominant – ABC Science

Author(s) Details: Khaled Jadallah Department of Internal Medicine, King Abdullah University Hospital, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan. Roberto De Giorgio Department of Translational Sciences, University of Ferrara, Ferrara, Italy. Rami Jadallah Department of Internal Medicine, King Abdullah University Hospital, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan. This section is a part of the chapter: Pharmacological Ad-vancements in the Management of Constipation-Predominant Irritable Bowel Syndrome: A Comprehensive Review Advancing treatment strategies for IBS-C necessitates a thorough understanding of the underlying pathophysiological abnormalities associated with each symptom of this complex disorder. This chapter will appraise the current knowledge on traditional and most advanced treatment options for IBS-C. Specifically, it systematically evaluates their efficacy, tolerability, and safety as demonstrated through clinical trials, while also providing a comprehensive overview of various laxative-based treatment options available for IBS-C. The review emphasizes key drug classes that have received considerable attention in recent research, including prokinetics, prosecretory agents (secretagogues), and bile acid modulators. Additionally, it addresses treatments that are presently under development for IBS-C. Moreover, the review recognizes the overlap between IBS-C and chronic idiopathic constipation (CIC) and examines pharmacological agents that have received regulatory approval or are currently under investigation for CIC, which may also offer therapeutic benefits for IBS-C. For example, lubiprostone, initially developed for CIC, has subsequently attained approval for the treatment of IBS-C (Chang et al. 2022, Schey and Rao 2011). It is important to clarify that this review does not include non-pharmacological interventions, such as fiber supplements and probiotics. How to Cite Jadallah, K., Giorgio, R. D., & Jadallah, R. (2025). Pharmacological Advancements in the Management of Constipation-Predominant Irritable Bowel Syndrome: A Comprehensive Review. Medical Science: Trends and Innovations Vol. 4, 49–85. https://doi.org/10.9734/bpi/msti/v4/4177 To Read the Complete Chapter See Here

Tag: predominant

Exploration of: Pharmacological Ad-vancements in the Management of Constipation-Predominant Irritable Bowel Syndrome